Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paladin’s Impavido Poised For Smooth Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reviewers did not identify any major problems with the application for treatment of three types of leishmaniasis, but did say the product may face resistance problems as use expands.

You may also be interested in...



FDA Antibiotic Restrictions Highlighted In Impavido Review

Advisory committee members, worried about adherence to miltefosine regimen outside the U.S., urge FDA to require directly observed therapy in labeling.

Impavido Gets Big Thumbs Up, Weighed Down By Dosing Concern

Anti-Infective Drugs Advisory Committee votes to recommend approval of leishmaniasis treatment, but questions about a post-marketing study on dosing in heavier patients linger.

Paladin’s Impavido Could Set A Price Tag For Priority Review Vouchers

Approval of the leishmaniasis treatment by its December user fee date would give the Canadian sponsor a voucher for a priority review, which it is likely to sell to another company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel